New & Notable
GLP-1 type 2 diabetes
New research links GLP-1 use in type 2 diabetes to slightly higher risks of optic neuropathy and diabetic retinopathy, with study authors urging regular preventative eye exams.
Exploring Red No. 3 ban reformulation strategies for Rx, OTC drugs
By Jan. 15, 2028, drug makers must rethink their approach to excipients, stability and color strategy to remove Red No. 3 from ingested prescription and over-the-counter products.
Trump's pharma import tariffs threaten drug pricing, generics
Trump's plan to raise pharma import tariffs up to 250% could drastically increase drug prices, eliminate access to affordable generics and limit R&D efforts across the industry.
HHS ends $500M in BARDA‑funded mRNA vaccine developments
With no announced timeline, HHS moves to terminate all mRNA vaccine development funded by BARDA, impacting 22 projects worth roughly $500 million.
Insights
Insights is research conducted by and for TechTarget Xtelligent Healthcare. Our work aims to leverage Xtelligent’s diverse readership of healthcare professionals across various sectors of the industry to understand real-world challenges and identify effective solutions.
Access All Reports
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
FDA updates opioid pain medication labeling requirements
The FDA will soon require opioid makers to update safety labels to highlight the risks of addiction, misuse, overdose, high doses and long-term use.
-
Trump urges top drugmakers to cut U.S. prescription drug costs
Trump increases pressure on 17 of the world's largest drug makers to lower U.S. prescription drug prices in 60 days, ahead of proposed tariffs and pharmaceutical import fee hikes.
-
Lilly's Mounjaro rivals Trulicity in cardiovascular risk reduction
Mounjaro rivals its GLP-1 predecessor, Trulicity, in reducing cardiovascular events in type 2 diabetes and outperforms in A1C reduction, weight loss and cardiovascular biomarkers.
-
Monarez becomes first CDC Director requiring Senate approval
Susan Monarez is the first CDC director subject to Senate approval and the first non‑physician in 70 years to lead the agency.
-
Mail-order, retail pharmacies outpace chains in patient satisfaction
Driven by better digital access and satisfaction scores, patients are favoring mail-order, supermarket and mass merchandiser pharmacies over chain drugstores.
-
FDA regulatory gaps fuel unsafe compounded GLP-1 drugs
Regulatory loopholes let compounders mass-produce untested GLP-1 drug knock-offs under the guise of personalization, prompting urgent FDA action to ensure patient safety.
Features
-
Understanding the importance of randomized clinical trials
Randomized controlled trials are the gold standard for proving therapeutic value, drug safety and efficacy, shaping pricing, reimbursement and securing regulatory approval.
-
How oral GLP-1 drugs could disrupt the weight loss market
FDA-approved oral GLP-1 formulations for weight loss could disrupt the weight management market, outcompete injectables and reduce patient access barriers.
-
Understanding pharmaceutical patent thickets, exclusivity
Pharmaceutical companies increasingly rely on dense patent thickets, including continuation patents, to delay competition, extend exclusivity and protect profits.
-
How digital twins are reshaping clinical trials
As drug development costs soar and timelines tighten, AI digital twins help sponsors cut enrollment, speed timelines and improve trial design, while meeting regulatory standards.